DZ Bank Reaffirms “Neutral” Rating for Merck KGaA (FRA:MRK)

DZ Bank restated their neutral rating on shares of Merck KGaA (FRA:MRK) in a research report released on Tuesday, November 14th.

Several other research firms have also recently issued reports on MRK. Oddo Bhf set a €125.00 ($148.81) price objective on Merck KGaA and gave the stock a buy rating in a report on Friday, November 10th. Morgan Stanley set a €103.00 ($122.62) target price on Merck KGaA and gave the company a neutral rating in a report on Monday, September 25th. Credit Suisse Group set a €106.00 ($126.19) target price on Merck KGaA and gave the company a neutral rating in a report on Wednesday, July 26th. Goldman Sachs Group set a €105.00 ($125.00) target price on Merck KGaA and gave the company a neutral rating in a report on Thursday, August 17th. Finally, Kepler Capital Markets set a €119.00 ($141.67) target price on Merck KGaA and gave the company a buy rating in a report on Monday, July 31st. Eleven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of €108.52 ($129.20).

Merck KGaA (MRK) traded down €0.04 ($0.05) during mid-day trading on Tuesday, hitting €89.39 ($106.42). The stock had a trading volume of 703,336 shares. Merck KGaA has a 1-year low of €87.99 ($104.75) and a 1-year high of €115.00 ($136.90).

TRADEMARK VIOLATION NOTICE: This report was published by BBNS and is the sole property of of BBNS. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/markets/merck-kgaas-mrk-neutral-rating-reiterated-at-dz-bank-ag/1782280.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.